Gabapentin Tablet
Product Images NDC 68788-7757

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-7757). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin 800mg 500tab

Gabapentin is a medication that comes in a tablet form of 800mg and is used as a prescription for patients only, as per Federal Law. The tablets are generic for Neurontin Gabapentin Tablets, USP 800mg and manufactured by ScieGen Pharmaceuticals. The tablets should be stored at a temperature range of 20°C to 25°C (68°F to T1°F) away from the reach of children. The packaging contains important information such as lot number, batch number, and the expiration date. The tablets are white in color and imprinted with "11/8 G".*

FDA Label Image

Figure 1 (Image 01)

This text represents a chart that shows the mean pain score for different treatment methods over a period of weeks. The treatment methods include a placebo and gabapentin at a dose of 3600mg/day, with two different dose titration periods. The chart shows the baseline and pain scores at four weeks.*

FDA Label Image

Figure 2 (Image 02)

This is a graph showing the mean pain score over a 4-week fixed dose period for participants taking a placebo or gabapentin at either 1800mg/day or 2400mg/day. The X-axis shows the weeks and the Y-axis shows the pain score.*

FDA Label Image

Figure 3 (Image 03)

FDA Label Image

Cockcroft And Gault Equation (Image 04)

FDA Label Image

Gabapentin Structural Formula (Image 05)

FDA Label Image

Figure 4. Responder Rate In Patients Receiving Gabapentin Expressed As A Difference From Placebo By Dose And Study: Adjunctive Therapy Studies In Patients ≥12 Years Of Age With Partial Seizures (Image 09)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.